Brimonidine vs ALTP in Progressing Human Glaucoma

• Status: Completed
• Trial end date: 2002-10-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is evaluating possible non-intraocular pressure (IOP) related effects of the alpha-1 agonist brimonidine in human subjects affected by a progressive glaucomatous optic neuropathy. Brimonidine was proven as neuroprotective in several pre-clinical animal studies.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Parma
• Treatments: Brimonidine Tartrate

Criteria

Inclusion Criteria:

• Glaucomatous visual field defect on achromatic perimetry (24/2 Humphrey full threshold,abnormal GHT and CPSD, p<0.01) considered clinically "unstable"

• IOP < 20 mmHg on repeated readings with no more than 2 medications,

• Open angle on gonioscopy,

• Glaucomatous optic neuropathy (HRTII, Moorfields regression analysis),

• Clear lens (LOCS2 score < C1, N0, P0)

• Best corrected visual acuity better than 0.2 LogMAR (ETDRS chart),

• No previous bulbar surgery

• Manifest refraction within - 5 and + 2 diopters

• No comorbidity (AMD and diabetic retinopathy.and negative history for neurological diseases)

Exclusion Criteria:

• Closed angle

• Previous bulbar surgery

• Unstable IOP

• Unreliable visual fields on historic data